A monthly PCSK9 shot cut LDL about 56% on top of statins
In the phase 3 LIBerate-HR trial, lerodalcibep lowered LDL cholesterol 56.2% more than placebo at 52 weeks on top of statins. It won approval in 2026; no outcome trial has yet reported.
Inclisiran beat bempedoic acid on LDL cholesterol in a head-to-head
In the Novartis-funded VICTORION-Challenge trial, twice-yearly inclisiran cut LDL 56.3% at day 150 against 15.4% for daily bempedoic acid — an open-label comparison of a surrogate marker, not outcomes.
An oral PCSK9 pill cut LDL 65% and beat every other oral nonstatin drug
In the phase 3 CORALreef AddOn head-to-head, enlicitide dropped LDL cholesterol 64.6% at day 56 — far past ezetimibe, bempedoic acid, or the two combined.
FDA approves the first pill in a cholesterol drug class that has only ever been injectable
Lipfendra cut LDL cholesterol by more than half in two trials. Its significance is less the number than the format: a once-daily tablet where every prior PCSK9 inhibitor required a needle.
A PCSK9 inhibitor cut first heart attacks and strokes in people who had never had one
VESALIUS-CV randomised 12,257 patients with atherosclerosis or diabetes but no prior MI or stroke. Evolocumab reduced the three-point event rate from 8.0% to 6.2% over a median 4.6 years.